Table 4.

In vitro cytotoxicity assay data activity of compounds 3-4(a-d) and 5,6(a-h).

				IC50 (µM)a
Comps	R	R1	R2	MCF-7	A-549	HeLa	Panc-1
3a	F	-	-	2.1 ± 0.41	6.7 ± 1.05	6.4 ± 1.06	1.9 ± 1.20
3b	MeO	-	-	4.4 ± 2.14	6.1 ± 1.15	6.9 ± 1.71	5.9 ± 2.40
3c	Me	-	-	5.3 ± 1.02	6.6 ± 1.16	4.1 ± 1.03	4.6 ± 1.20
3d	H	-	-	9.1 ± 1.07	7.3 ± 2.01	6.2 ± 1.47	7.7 ± 1.50
4a	F	-	-	1.8 ± 0.51	1.9 ± 0.81	5.9 ± 1.7	4.9 ± 2.40
4b	MeO	-	-	9.1 ± 2.01	7.3 ± 2.21	6.2 ± 2.47	7.7 ± 0.05
4c	Me	-	-	8.4 ± 1.04	8.4 ± 2.11	9.9 ± 2.07	7.2 ± 1.50
4d	H	-	-	7.6 ± 2.17	7.9 ± 1.06	6.5 ± 2.04	7.4 ± 1.25
5a	F	Me	-	2.9 ± 1.17	10.9 ± 1.19	1.5 ± 0.51	9.4 ± 2.21
5b	MeO	Me	-	3.9 ± 1.10	2.3 ± 1.01	2.7 ± 1.04	2.5 ± 2.05
5c	Me	Me	-	6.3 ± 2.04	8.1 ± 1.25	7.2v1.07	6.1 ± 2.04
5d	H	Me	-	5.9 ± 3.00	6.1 ± 2.24	10.5 ± 1.05	9.7 ± 2.11
5e	F	H	-	0.90 ± 0.17	0.81 ± 0.80	0.8 ± 0.54	1.24 ± 0.90
5f	MeO	H	-	3.5 ± 0.73	5.0 ± 1.90	3.5 ± 1.14	5.5 ± 2.50
5g	Me	H	-	6.52 ± 0.45	4.9 ± 0.52	10.2 ± 1.14	8.91 ± 0.20
5h	H	H	-	4.4 ± 1.90	3.8 ± 0.57	4.7 ± 1.19	5.7 ± 1.60
6a	F	-	4-FPh	1.3 ± 0.92	1.6 ± 0.60	1.6 ± 0.14	1.7 ± 0.91
6b	MeO	-	4-FPh	4.1 ± 2.70	1.01 ± 0.29	7.6 ± 0.80	1.0 ± 0.72
6c	Me	-	4-FPh	4.7 ± 1.14	4.70 ± 0.66	6.45 ± 2.73	5.4 ± 1.12
6d	H	-	4-FPh	0.79 ± 0.50	1.8 ± 1.29	1.5 ± 0.35	1.12 ± 0.58
6e	F	-	4- MeOPh	1.91 ± 0.20	15.7 ± 0.50	1.8 ± 0.90	10.5 ± 0.22
6f	MeO	-	4-MeOPh	7.2 ± 1.35	11.4 ± 1.20	10.5 ± 1.81	9.7 ± 2.11
6g	Me	-	4-MeOPh	8.6 ± 1.32	9.9 ± 1.24	10.1 ± 1.42	9.4 ± 1.09
6h	H	-	4-MeOPh	3.6 ± 1.54	7.9 ± 2.19	8.1 ± 1.05	6.4 ± 1.05
Doxorubicin -				0.92 ± 0.50	1.02 ± 0.80	1.02 ± 0.72	1.41 ± 0.58

^aIC₅₀ values are indicated as mean ± SD of three independent tests.